Good morning. Welcome everybody to day two of the Jefferies Healthcare Conference this year. My name is Michael Leuchten. I am one of the European Pharma Analysts at Jefferies. Thank you for joining us early. It is my pleasure to host GSK today. We have got David Redfern, the Head of BD at GSK, or President of BD, is also responsible for ViiV. I think we will do a little bit on ViiV, then we will do BD, and then a little bit broader on GSK and the recent changes. I hope I can make that work in 25 minutes. David, thank you for joining.
Maybe just starting with ViiV, I think you chaired it since 2011, and looking back, what would you say are the two or three decisions that most changed the direction of the business, and what lessons have been most relevant as we think about your transition of the portfolio to the long-acting injectables?
Great. Well, good morning everyone. Thanks, Michael, for having us. Thanks for Jefferies hosting everyone. Next year, you just need to fix the weather a little bit, I think. It is a great question on ViiV. I think probably two things, actually. If you go way back, when we developed dolutegravir, which is the oral integrase inhibitor that has really become the backbone standard of care, we knew we had a very potent molecule from the animal studies from phase II, 50 mg, very well tolerated. I think one of the key things we did in that phase III development program was not just study dolutegravir in virally suppressed patients, which was the normal, but we ran in parallel all types of people living with HIV, so people who had high viral load, naive patients, and so forth.
When we got approval for dolutegravir, we had a very, very broad label, and obviously it has gone on to be an enormous medicine. I think the second key thing was a decision we took over a decade ago to really focus our R&D money on long-acting. That was not a completely obvious decision because the daily orals in HIV had become very, very effective. If you talked to most doctors at that time, they were very satisfied. But there were two sort of key insights. One was patient insight. There were quite a significant number of people living with HIV that did not want to take daily oral pills every day. They felt a degree of stigma, anxiety, had not necessarily disclosed their status, and they really wanted to move to a long-acting injection.
And also, unfortunately, in the U.S., of the 1.2 million people living with HIV, only 60% or so are virally suppressed, despite the modern medicine. That is everything to do with access to the healthcare system. So there are still over 400,000 to 500,000 Americans that living in the rural South, lower income inner city, particularly African Americans, who are not virally suppressed. The only way to really treat that population effectively is with a long-acting injection. So we invested in that. Obviously, we launched the first medicine, Cabenuva, for treatment. That is every two months, and that is now grown into a very significant medicine and doing extremely well.
Great. Thank you. Then maybe one more on ViiV before I think most people are probably more interested in BD and GSK going forward. The long-acting strategy there is Cabenuva Q4M, so every four months.
Yeah.
Then there is the every six monthly, which is a bit further out. Can you just talk about timelines? Can you talk about, there was a slight hiccup with the Q4M PK/PD study. We are going to get CUATRO next year, which is the treatment every four months, Cabenuva. Just paint that picture, like what is the confidence into Cabenuva Q4M and into every six months with 184 and 499? Sorry, 184.
Yes. I mean, you have to separate the treatment market, which is about 90% of the overall HIV market, over GBP 22 billion from the PrEP prophylactic market, which is predominantly a U.S. market, about GBP 3 billion. So in treatment, we have the first and only long-acting medicine on the market. As I said, Cabenuva doing very, very well now with very comprehensive dataset. We have a reformulated version of cabotegravir and rilpivirine in a pivotal study, the CUATRO study that you referred to. That has fully recruited, and we expect data on that probably the second half of next year. So that would potentially be on the market in 2028. Then we are developing a next generation integrase with a much broader resistance barrier, 184, with our own capsid inhibitor. That has the potential to be a sixth monthly regimen.
Both of those molecules are in phase II studies at the moment, and we are figuring out the formulation and the dose. We would hope to put those into pivotal studies probably somewhere around mid-2028. If we do that, we could potentially get that on the market early 2030s. I think that, as we move from every two months to every four months and then every six months, we will see a significant increase in the penetration of long-acting in the overall HIV treatment market. Certainly when we get to every six months, I think up to at least half the market could potentially switch. So that is very exciting. In PrEP, as you said, we have Apretude, which is every two months, doing pretty well in a growing market.
We have got data in-house on the four-month version of that, and we are in discussions with the regulator with that. I am not going to say more about that other than we are very, very confident in the formulation that we have got. The formulation actually of PrEP and the four-month version of cabotegravir is the same.
Got it. Okay. Amazing. Let us maybe pivot to BD. You have overseen corporate development across several different strategic eras at GSK. Can you talk about the philosophy of BD today and how it has changed, and what is distinctive about the current approach that you are pursuing?
We have been very active in BD this year and actually the last two or three years. Ever since, really, we demerged the Haleon business, the consumer business, reset the balance sheet, and became a pure play biopharma business. Like most large-cap pharmas, BD is an essential part of how we allocate capital. There is obviously fantastic science throughout the world to access. This year, we have done three pieces of M&A. We bought Nuvalent in the middle of the year, Boston-based precision oncology company.
That was important to us because it was an important building step as we redevelop our oncology business, which is now going extremely well, and it gave us an entry into lung cancer for the first time. It has two precision molecules for ALK and ROS1 inhibitor. The ROS1 has been approved. The ALK we expect to be approved any day. So that is going well.
Behind that, in our own portfolio, we have a B7-H3 ADC from Hansoh that could also. We are in a pivotal study for small cell lung cancer at the moment, and potentially we are going to non-small cell lung cancer. There is no doubt under Luke Miels' now leadership, GSK is very much back in oncology, both blood cancers and solid tumors. We have a pretty extensive portfolio now. We are allocating a lot of capital to it, and you should certainly expect us to do more BD in oncology. We bought RAPT Therapeutics in the start of the year that has a food allergy antibody, very similar, same epitope as Xolair. Food allergy, as you can imagine, is growing very, very fast. Something like 18 million people in the United States have a significant food allergy.
RAPT is really quite indicative of the deals we like, where there is some level of scientific de-risking, normally the target. In this case, the epitope, as I said, is, I think, de-risked from Xolair, but with very, very clear differentiation. In all the deals we do, being absolutely clear what the point of differentiation is absolutely critical. In this case, the dosing regimen is every 12 weeks. It has a much simpler dosing regimen than Xolair, and it also, the problem with Xolair is because of the maximum dosing, it cannot be used in people with food allergies over a certain BMI and weight, whereas R1 can. So that is exciting. Then we have done a whole bunch of licensing deals, some from the U.S., some from China. We have been pretty active in China. I think we will continue to be.
Most of our Chinese licensing is phase I. So we like, and we have obviously done deals with Hengrui, with Hansoh. We are very excited about the ADCs that I talked about that we have got from Hansoh. But phase I is a sweet spot because you have got some human data, but then the ability to run the pivotal studies in the markets you want regulatory approval, and also to move the supply chains across. So, we have been active. You should certainly expect us to continue to be active as we finish this year and go into next year.
Great. Can we maybe go a little bit deeper into that point? You did Nuvalent. We like that deal a lot. But you used a lot of your balance sheet capacity if we sort of look at the total of capital deployed. Is now a reload time? Do you have capacity to do sizable deals, or is it more consolidating now?
It is a bit of both. We have definitely got more balance sheet capacity available. We are really governed by our credit rating. We like staying at A2. Of course, the cash flow of the business is extremely strong. We expect cash flow from operations to be over GBP 10 billion this year. So, the balance sheet is replenishing pretty fast. I think we are about 1.8x levered at the moment. It is not just balance sheet capacity, it is P&L capacity and also management capacity. We have got plenty to do. You should, as I said, we will do more, and we have got more capacity. I would not expect us to do another $10 billion deal this week. We will leave that to others. Most of the deals up to Nuvalent were typically in the $2 billion-$3 billion range, and we quite like that sort of level.
Got it. Maybe another way to look at BD is, the assets that you acquired, you said you go after the differentiation, it fits your setup already. What you have not done is platform deals, or at least not yet. Is that something that you do not think GSK needs right now to branch out into other areas, or is it just a timing question?
It depends what you mean by platform deals. We access a lot of technology. We obviously, like all pharma companies, we are doing a lot on AI. Part of that actually is accessing human databases. So we have access here in the U.K. to the Biobank, to the NHS. We have got access to things like Tempus in oncology, some of the insurance data in the U.S. I think increasingly, the algorithms matter, but having the quality longitudinal human data to help in the work we are doing, combining that with AI to identify novel targets is critical. So, there is plenty going on there. We access all sorts of different technologies. I will give our friends at Engitix, who are in the room, a plug. It is a U.K.-based biotech, where we are working and collaborating with in liver disease. So, we do.
They tend to be smaller and earlier stage, so probably get less headlines, but we do plenty.
Okay. Got it. Then maybe because you mentioned Hansoh, I think you moved early on that. You were one of the earlier companies to go into these sort of deals with China. It has become more crowded. Is that still a source of deal flow for you? Do you think it will accelerate quality of assets, readability of Chinese data into rest of world? You mentioned you got there, but you had to find out ways to replicate data for regulatory approval outside China.
We never start from the point of view that we are going to go to China and see what we can find. We start with, we identify a mode of action or a molecule we particularly want, then decide who has the best one. That is exactly what happened with Hansoh. We were very keen as we built our oncology business to have a B7-H3, B7-H4, ADC, two ADCs. We looked around, obviously, Merck licensed the Daiichi ones for quite a lot of money. We did a lot of work with all the different options, and we ended up doing the deals with Hansoh, which has worked so far incredibly well. I think it is interesting because particularly in oncology, as you know, China. Hansoh has the rights in China, we have the rest of the world.
They are running about 18 months ahead of us with the studies that they are doing in China. That is incredibly informative because it is a good proof point. So they already have, they showed very good data with overall survival benefit, at World Lung, in small cell lung cancer in second line. We are running the pivotal study there. They showed great data in osteosarcoma. They are running studies in non-small cell lung cancer and a whole range of other solid tumors. So that is useful data, because it enables us to sort of make our own choices of exactly which tumor types to go for. I have to say, so far, the data that we have got from the Western studies, mainly phase II studies, has replicated almost exactly. We are super excited about both of those ADCs.
As I said, small cell lung cancer is going very, very fast and potentially have the opportunity to file that as early as next year. Then we have five pivotal studies now running on B7-H4 in ovarian and endometrial cancer, first and second line. So I think, look, China, we all know the innovation has moved very fast. It is in certain areas. They are extremely good at protein engineering. They are extremely good at building ADCs. They have moved from sort of fast followers to probably, in some cases, best in class. We have also licensed some trispecifics, some bispecifics from Chimagen, and HUTCHMED and so forth. So, particularly in that protein, complex protein molecules, they are very good. But we are still doing plenty of deals in America and elsewhere.
Got it. I want to try to link the ViiV, BD, and P&L comment that you make together in a minute. Before we do that, with your experience on BD, there have been transactions that unfortunately haven't worked out, like BELLUS. When you take a step back, what's the biggest source of value leakage when you do deals? Is it cultural friction, development slower, loss of key scientists? Where?
Well, the biggest source of leakage is when the molecule doesn't work. That's fairly obvious. I would say we put a lot of attention on CMC, and CMC rarely derails an asset, but it can very easily slip timelines. One of the key parts that we do is really thinking through the robustness of CMC and whether it's consistent with the timelines that we build in the models or the timelines that are stated. There's lots of ways it can go wrong, as we're doing more and more complicated medicines. It's always a combination of things. I have to say overall, you're right, obviously BELLUS, which was reasonably high risk, didn't work out.
Most of the recent deals that we've done, and we do a very serious exercise every year to compare the original assumptions with the most recent forecasts, are running quite a way ahead. The Sierra acquisition where we got Ojjaara, momelotinib, and myelofibrosis is flying. We talked about the ADCs. Actually, even Tesaro, because while Zejula has probably underperformed a little bit, Jemperli is doing extremely well, dostarlimab, in endometrial cancer and just about to be rectal cancer. Yeah, overall, I think the BD has been a key driver of our growth.
Got it. If we try to link the ViiV commentary, the BD and P&L impact, and then new GSK, if I can call it that, together. 2027 is a year where I think things are relatively normal, and then from 2028, it gets a little bit more choppy because there are some lots of exclusivities that start to fade in. High profitable stuff slowing down gives you negative mix effect. You've announced a major restructuring program, but then you have done BD and you continue to do BD. Can you talk a little bit about the shape of that balance into 2028, 2029, and then beyond where the long-acting new generation comes in? That in-between period, where do you think the main focus is? Is it the restructuring program?
Is it do more BD to pad out the assets that can go into market quickly? Is it all of the above?
Well, I think it is all the above, but I particularly flag we have had over 20, I think it is now 22 phase III starts this year. So obviously, as those read out next year and in 2027 and 2028, that is the backbone of the future growth of GSK. I think, as you said, the way to think about GSK is we are performing very strongly the last few years. We have upgraded again this year to mid-single digit or the top end of our 3%-5% sales growth, and the top end of our 7%-9% operating profit growth. Next year, there are puts and takes, but broadly, as you have said, we will guide next year, but we certainly expect to grow strongly next year, and not decline the operating margin. As we go into 2028, the dolutegravir patent expiries start on a major way.
We lose in April 2028 in the U.S., Tivicay and Triumeq. Dovato is right at the end of 2029. Europe is also in 2029. So the HIV business will decline particularly in 20, I mean, to some degree in 2028, but the main declines will be in 2029 and 2030, despite the fact that long-acting will continue to grow and offset some of the oral decline. But overall, we are very clear. We expect GSK to grow through the dolutegravir period, which is why we have given an outlook of more than GBP 40 billion in 2031, recognizing sales today are plus or minus this year around GBP 35 billion. That is driven mainly by the specialty business that is already launched, our growing oncology business, medicines like Nucala, Exdensur in respiratory, as well as vaccines.
Then I think the most exciting thing about GSK, and you guys on the sell side need to focus a little bit more on it as we move forward, is as we get to the other side of dolutegravir in the early 2030s, I think we really have the ability to accelerate our growth to top quartile in the industry. Because as the pipeline comes through, the ADCs, the investments we have made in liver disease with things like FGF21, our biologics in respiratory, so our long-acting TSLP, our long-acting IL-33, our long-acting in HIV, vaccines where we have our flu mRNA program already in pivotal studies, and all the various tumor types in oncology, and then our precision oncology in velzatinib.
If you put all that together, once we're the other side of the patent expiry, I think we can really accelerate very strongly, and that should lead to a significant re-rating. Obviously, there's a lot of execution attached to that. We recognize that. We're very focused, I think, on execution. Part of that is taking out or delivering GBP 1.9 billion of costs by 2029. Most of that will be reinvested in R&D, and that's a key part of it. Of course, on top of all of that, we're not going to slow down on BD.
Got it. In the last few minutes, I think you joined GSK in 1994. You've sort of seen a number of strategic approaches. The restructuring program that you mentioned of GBP 1.9 billion, can you talk about how that compares to maybe prior programs? Also interested in the decision to move from Stevenage to Cambridge from an R&D perspective. How different is that, and what impact do you think that will have on the organization?
Well, I mean, look, restructuring, we haven't done a major restructuring for five years, so it felt like the right time, and obviously with a new CEO. It is across the whole value chain. There's opportunities in our supply chain. As we move to more specialties, some of the older manufacturing sites that serve the general medicines business have become surplus to requirements. Of course, with technology, we've got multiple service centers around the world, but there is an opportunity to consolidate those to some degree and also drive even more automation into those, and so forth. The restructuring is not particularly different or surprising compared to what a lot of multinationals are doing, really taking advantage of tech. I mean, in terms of the move from Stevenage to Cambridge, I think that makes complete sense. It's been relatively uncontroversial.
I think, we're very fortunate in this country. The Cambridge ecosystem is amazing—
Yep.
—and growing. Stevenage has been a great site for 30 years, but it is too large for the way we would now work. It has too many wet labs. I think the scientists increasingly want to be part of a broader ecosystem and have the opportunity to interact. We will do that over the next two years. Most people at Stevenage will move to Cambridge. A few will move to our manufacturing and pilot plant site in Ware, where we do a lot of drug formulation work. We are pretty excited about that and excited about being part of the Cambridge ecosystem.
Perfect. Last question. If, let us say in five years' time, we do this again in rearview mirror, what do you think is the most important thing GSK needs to get right so in five years' time we have a conversation where we go. Yep.
I would love to think in five years' time we have a really, really material and fast-growing oncology business. I mean, it is about GBP 2 billion today. I think it could be multiples bigger than that.
Got it. Great. Right on time. Thank you, Dave.
Thanks.
Very efficient.
Very efficient. Yeah, thank you.